CN115811988A - 一种血液净化分子浓缩物及其制备方法与应用 - Google Patents

一种血液净化分子浓缩物及其制备方法与应用 Download PDF

Info

Publication number
CN115811988A
CN115811988A CN202180032036.6A CN202180032036A CN115811988A CN 115811988 A CN115811988 A CN 115811988A CN 202180032036 A CN202180032036 A CN 202180032036A CN 115811988 A CN115811988 A CN 115811988A
Authority
CN
China
Prior art keywords
acid
citrate
percent
blood purification
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032036.6A
Other languages
English (en)
Inventor
冯克民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN115811988A publication Critical patent/CN115811988A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

一种血液净化分子浓缩物，其为固体状态的制剂或液体状态的制剂，含有酸碱调节剂和以分子形式存在的物质，所述酸碱调节剂为L‑苹果酸、DL‑‑苹果酸、马来酸、富马酸、琥珀酸与枸橼酸钙、枸橼酸钠、枸橼酸镁、枸橼酸钾的一种或两种或多种混合物。

Description

PCT国内申请，说明书已公开。

Claims (6)

  1. PCT国内申请，权利要求书已公开。
CN202180032036.6A 2020-05-22 2021-05-21 一种血液净化分子浓缩物及其制备方法与应用 Pending CN115811988A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010446821.3A CN111714515A (zh) 2020-05-22 2020-05-22 一种血液净化分子浓缩物及其制备方法与应用
CN2020104468213 2020-05-22
PCT/CN2021/095226 WO2021233432A1 (zh) 2020-05-22 2021-05-21 一种血液净化分子浓缩物及其制备方法与应用

Publications (1)

Publication Number Publication Date
CN115811988A true CN115811988A (zh) 2023-03-17

Family

ID=72564958

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010446821.3A Withdrawn CN111714515A (zh) 2020-05-22 2020-05-22 一种血液净化分子浓缩物及其制备方法与应用
CN202180032036.6A Pending CN115811988A (zh) 2020-05-22 2021-05-21 一种血液净化分子浓缩物及其制备方法与应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010446821.3A Withdrawn CN111714515A (zh) 2020-05-22 2020-05-22 一种血液净化分子浓缩物及其制备方法与应用

Country Status (2)

Country Link
CN (2) CN111714515A (zh)
WO (1) WO2021233432A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111714515A (zh) * 2020-05-22 2020-09-29 夏永彪 一种血液净化分子浓缩物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109106724A (zh) * 2017-06-23 2019-01-01 刘成其 一种苹果酸碳酸氢盐体外血液透析剂
CN109498646A (zh) * 2018-11-16 2019-03-22 秦皇岛迈淩医疗设备有限公司 一种血液透析用固体制剂及其制备方法
CN111714515A (zh) * 2020-05-22 2020-09-29 夏永彪 一种血液净化分子浓缩物及其制备方法与应用

Also Published As

Publication number Publication date
CN111714515A (zh) 2020-09-29
WO2021233432A1 (zh) 2021-11-25

Similar Documents

Publication Publication Date Title
AU2002356899B2 (en) Bicarbonate-based solutions for dialysis therapies
Fassler et al. Magnesium toxicity as a cause of hypotension and hypoventilation: occurrence in patients with normal renal function
JP2009131669A (ja) 単一容器中にある重炭酸塩ベースの溶液
US20080044490A1 (en) Sterile low bicarbonate dialysis concentrate solutions
CN115811988A (zh) 一种血液净化分子浓缩物及其制备方法与应用
CN116056715A (zh) 血液净化浓缩物
JP6425661B2 (ja) 透析組成物
Hoenich et al. Haemodialysis fluid: composition and clinical importance
CN101756949A (zh) 一种盐酸氨溴索与半胱氨酸的组合物及其制备方法
CN103638526B (zh) 一种血液净化用制剂及其制备方法与应用
CN111821532A (zh) 一种置换液配方的精准调钠方法
Leunissen et al. Chronic haemodialysis with bicarbonate dialysate: technical and clinical aspects
EP2609915B1 (en) Dialysis and substitution fluid
CN109106724A (zh) 一种苹果酸碳酸氢盐体外血液透析剂
CN107854486A (zh) 供注射用的多种微量元素的药物组合物及其用途
AU2008201009B2 (en) Bicarbonate-based solutions for dialysis therapies
Koda et al. Persistent metabolic acidosis in a hemodialyzed patient with short bowel syndrome
CN117919274A (zh) 一种血液透析浓缩物
CN117100905A (zh) 促进伤口愈合的敷料
WO2014138723A2 (en) Physical optimization beverage
JP2020164507A (ja) 分子状水素を含む腎臓疾患の腎機能改善のための組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination